Rocket Pharmaceuticals, Inc. (RCKT) Earnings Call Transcripts
Rocket Pharmaceuticals, Inc.'s Latest Earnings Call - June 9, 2026
In the Q2 2026 earnings call, Rocket Pharmaceuticals (RCKT:US) highlighted significant progress in its gene therapy pipeline, particularly in cardiovascular genetic medicines. The company reported a strong cash position following the sale of a Priority Review Voucher (PRV) for $180 million, extending its cash runway into Q2 2028. Management expressed confidence in upcoming catalysts, including updates on pivotal trials for Danon disease, PKP2, and BAG3, which could unlock substantial revenue opportunities, each potentially exceeding $1 billion. Despite these advancements, the stock remains down 10% year-over-year, indicating market skepticism that management aims to address through milestone achievements.
Reported metrics
| Metric | Value |
|---|---|
| Cash Runway | $180M (positive) |
| Stock Performance | -10% (negative) |
| Revenue Opportunity per Program | $1B+ (positive) |
| FDA Approvals | 1 (positive) |
| Patients Dosed in Danon Trial | 3 (positive) |
| Clinical Programs | 3 (positive) |
Guidance from management
Management indicated that they expect to provide updates on pivotal trial designs and regulatory paths later in 2026, maintaining a focus on executing their strategic priorities without raising or lowering guidance at this time.
What management said
We're in the midst of that. So in addition to everything that Gaurav just mentioned, Rich, I'd also say that beginning in 2025, we made the announcement when we came out with earnings from the prior year. So when we announced our 10-K last year, we said that we're leaning into the cardiovascular genetic medicines company. However, Rocket's origin is -- has a legacy, and that just takes time. So I think that we're i...
So we're still in those discussions. And both -- especially Fanconi Anemia. Fanconi Anemia is a program that is near the end goal of being ready for BLA submission. The data have only matured and improved over time on the clinical side. So in the right hands, I think that this can get to patients soon. So we're exploring that. PKD is an earlier-stage program. When gene therapy works, it works. We demonstrated that ...
What analysts pressed on
Analysts expressed concerns regarding the stock's underperformance despite recent approvals and the need for clear communication on upcoming milestones. There is also apprehension about the competitive landscape in gene therapy and the potential for additional regulatory hurdles.
Main topics on the call
- Regulatory Progress and Approval — Rocket received its first FDA approval for KRESLADI for severe LAD-I, marking a significant milestone. CEO Gaurav Shah stated, "We got the KRESLADI approval. We got the Danon trial back up and running." This approval is ...
- Clinical Trial Updates — Management provided updates on ongoing clinical trials, particularly for Danon disease, PKP2, and BAG3. They indicated that the pivotal study for Danon has resumed and that they are dosing patients under a revised regime...
- Market Sentiment and Stock Performance — Despite recent advancements, the stock price remains down 10% year-over-year, suggesting that the market is still cautious. Gaurav Shah noted, "I think this is a show-me story," indicating the need for tangible results t...
- Cash Position and Runway — Following the PRV sale, Rocket's cash runway has been extended into Q2 2028, providing ample time to execute on its clinical programs. Meg Dodge mentioned, "Our cash runway has been extended with the monetization of that...
Read the full Rocket Pharmaceuticals, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (RCKT) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 34 calls on record spanning January 14, 2020 to June 9, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 34 Rocket Pharmaceuticals, Inc. earnings call transcripts on record, spanning January 14, 2020 to June 9, 2026. Based on this history, Rocket Pharmaceuticals, Inc. reports quarterly. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- RCKT
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 34
- First call
- January 14, 2020
- Most recent
- June 9, 2026
- Reporting cadence
- quarterly